[1] Sciarra A, Park YN, Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma[J].Hum Pathol,2020,96:48-55. DOI:10.1016/j.humpath.2019. 11.001.
[2] Peng JB, Peng YT, Lin P, et al. Differentiating infected focal liver lesions from malignant mimickers: value of ultrasound-based radiomics[J].Clin Radiol,2022,77(2):104-113. DOI:10.1016/j.crad.2021.10.009.
[3] Schizas D, Mastoraki A, Routsi E, et al. Combined hepatocellular-cholangiocarcinoma: an update on epidemiology, classification, diagnosis and management[J].Hepatobiliary Pancreat Dis Int,2020,19(6):515-523. DOI:10.1016/j.hbpd.2020.07.004.
[4] Ramai D, Ofosu A, Lai JK, et al. Combined hepatocellular cholangiocarcinoma: a population-based retrospective study[J].Am J Gastroenterol,2019,114(9):1496-1501. DOI:10.14309/ajg.0000000000000326.
[5] 张瑜,刘秀峰,秦叔逵,等. 混合型肝癌的临床特征和预后分析[J]. 临床肿瘤学杂志,2019,24(8):738-742. DOI:10.3969/j.issn.1009-0460.2019.08.013.
[6] 邢红宇,黄淑玲,卓书伟,等. 血清载脂蛋白A1及B对老年肝细胞癌患者术后生存率的预测价值[J]. 中国老年学杂志,2020,40(20):4297-4300. DOI:10.3969/j.issn.1005-9202. 2020.20.013.
[7] 兆勇,李井野. 老年肝癌根治性切除术后肝癌复发的高危因素分析[J]. 现代肿瘤医学,2020,28(21):3745-3748. DOI:10.3969/j.issn.1672-4992.2020.21.023.
[8] 赵姣萍,许文芳. 预测老年早期肝癌患者术后发生肝衰竭的列线图模型建立[J]. 浙江中西医结合杂志,2020,30(9):767-770. DOI:10.3969/j.issn.1005-4561.2020.09.023.
[9] Araki K, Harimoto N, Kubo N, et al. Functional remnant liver volumetry using Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) predicts post-hepatectomy liver failure in resection of more than one segment[J].HPB (Oxford),2020,22(2):318-327. DOI:10.1016/j.hpb.2019.08.002.
[10] Takeishi K, Yoshizumi T, Itoh S, et al. Surgical indications for hepatocellular carcinoma with non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-Enhanced MRI[J].Ann Surg Oncol,2020,27(9):3344-3353. DOI:10.1245/s10434-020-08419-4.
[11] Yamada S, Shimada M, Morine Y, et al. A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging[J]. PLoS One,2019,14(1):e0210579. DOI:10.1371/journal.pone.0210579.
[12] Araki K, Harimoto N, Yamanaka T, et al. Efficiency of regional functional liver volume assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein tumor thrombus[J].Surg Today,2020,50(11):1496-1506. DOI:10.1007/s00595-020-02062-y.
[13] Romanzi A, Ariizumi S, Kotera Y, et al. Hepatocellular carcinoma with a non-smooth tumor margin on hepatobiliary-phase gadoxetic acid disodium-enhanced magnetic resonance imaging. Is sectionectomy the suitable treatment?[J].J Hepatobiliary Pancreat Sci,2020,27(12):922-930. DOI:10.1002/jhbp.743.
[14] Huang M, Shen S, Cai H, et al. Regional liver function analysis with gadoxetic acid-enhanced MRI and virtual hepatectomy: prediction of postoperative short-term outcomes for HCC[J].Eur Radiol,2021,31(7):4720-4730. DOI:10.1007/s00330-020-07606-x.
[15] Donadon M, Lanza E, Branciforte B, et al. Hepatic uptake index in the hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine penta acetic acid-enhanced magnetic resonance imaging estimates functional liver reserve and predicts post-hepatectomy liver failure[J].Surgery,2020,168(3):419-425. DOI:10.1016/j.surg.2020.04.041.
[16] Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications[J].J Hepatol,2021,74(1):109-121. DOI:10.1016/j.jhep.2020.08.013.
[17] Shimada S, Kamiyama T, Kakisaka T, et al. Impact of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging on the prognosis of hepatocellular carcinoma after surgery[J].JGH Open,2020,5(1):41-49. DOI:10.1002/jgh3.12444.
[18] Yamada S, Kishi Y, Miyake M, et al. Characteristics of false-positive lesions in evaluating colorectal liver metastases on gadoxetic acid-enhanced magnetic resonance imaging[J].Surg Today,2022,52(8):1178-1184. DOI:10.1007/s00595-022-02451-5.
[19] Chou YC, Lao IH, Hsieh PL, et al. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma[J].World J Gastroenterol,2019,25(21):2636-2649. DOI:10.3748/wjg.v25.i21.2636.
[20] Ishii T, Ito T, Sumiyoshi S, et al. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma[J].World J Surg Oncol,2020,18(1):319. DOI:10.1186/s12957-020-02099-w.
[21] Krishna M. Pathology of cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma[J].Clin Liver Dis (Hoboken),2021,17(4):255-260. DOI:10.1002/cld.1047.
[22] Su YL, Ng CT, Jan YH, et al. Remarkable response to olaparib in a patient with combined hepatocellular-cholangiocarcinoma harboring a biallelic BRCA2 mutation[J].Onco Targets Ther,2021,14:3895-3901. DOI:10.2147/OTT.S317514.
[23] Liu Z, Suo C, Mao X, et al. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017[J].Cancer,2020,126(10):2267-2278. DOI:10.1002/cncr.32789.
[24] Kwon SM, Budhu A, Woo HG, et al. Functional genomic complexity defines intratumor heterogeneity and tumor aggressiveness in liver cancer[J].Sci Rep,2019,9(1):16930. DOI:10.1038/s41598-019-52578-8.
[25] Navarro-Villarán E, de la Cruz-Ojeda P, Contreras L, et al. Molecular pathways leading to induction of cell death and anti-proliferative properties by tacrolimus and mTOR inhibitors in liver cancer cells[J].Cell Physiol Biochem,2020,54(3):457-473. DOI:10.33594/000000230.
[26] Li BH, Wang Y, Wang CY, et al. Up-regulation of phosphatase in regenerating liver-3 (PRL-3) contributes to malignant progression of hepatocellular carcinoma by activating phosphatase and tensin homolog deleted on chromosome ten (PTEN)/phosphoinositide 3-Kinase (PI3K)/AKT signaling pathway[J].Med Sci Monit,2018,24:8105-8114. DOI:10.12659/MSM.913307.
[27] Mano Y, Yoshio S, Shoji H, et al. Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma[J].J Gastroenterol,2019,54(11):1007-1018. DOI:10.1007/s00535-019-01579-5.
[28] Liu H, Cheng L, Cao D, et al. Suppression of miR-21 expression inhibits cell proliferation and migration of liver cancer cells by targeting phosphatase and tensin homolog (PTEN)[J]. Med Sci Monit,2018,24:3571-3577. DOI:10.12659/MSM.907038.
[29] Li X, Sun B, Zhao X, et al. Function of BMP4 in the formation of vasculogenic mimicry in hepatocellular carcinoma[J].J Cancer,2020,11(9):2560-2571. DOI:10.7150/jca.40558.
[30] 潘冰,陈慧,郑炜智,等. 原发性肝癌组织中BMP-4表达及临床意义的研究[J]. 重庆医学,2020,49(1):57-61. DOI:10.3969/j.issn.1671-8348.2020.01.012.
|